ID

37414

Description

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin; ODM derived from: https://clinicaltrials.gov/show/NCT02429258

Lien

https://clinicaltrials.gov/show/NCT02429258

Mots-clés

Versions (1)
  1. 24/07/2019 24/07/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

24 juillet 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type II Diabetes NCT02429258

Anglais

Eligibility Type II Diabetes NCT02429258

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes mellitus (t2dm)
Description

Diabetes Mellitus, Non-Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
treated with either stable dose of metformin alone > or = to 1500mg/day or stable dose of insulin > or = to 30 units/day and up to 2oad medications for at least 8 weeks
Description

Metformin Dose Stable U/day | Insulin Dose Stable U/day | Antidiabetics Oral Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [1,4]
C0456683
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [2,4]
C0456683
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [3,3]
C1265611
hemoglobin a1c (hba1c) 7.5% to 10.5% at screening
Description

Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
body mass index (bmi) < or = to 45 kg/m2
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
for patients who enter the study taking a stable dose of metformin, history of taking oad medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening
Description

Metformin Dose Stable | Antidiabetics Oral | Exception Metformin | Insulin regime

Type de données

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0025598
UMLS CUI [4]
C0557978
for patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 oad medications for 8 weeks prior to screening.
Description

Insulin | Therapy Except Insulin | Therapy Except Antidiabetics Oral

Type de données

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0332300
UMLS CUI [2,3]
C0021641
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0332300
UMLS CUI [3,3]
C0935929
UMLS CUI [3,4]
C1527415
use of sulfonylureas during the 8 weeks prior to screening
Description

Sulfonylureas

Type de données

boolean

Alias
UMLS CUI [1]
C0038766
prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (sglt-2) inhibitor
Description

Exposure to Dapagliflozin | Exposure to SGLT2 Inhibitor

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C2353951
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C3273807
ingestion of any medication know to affect glucose metabolism for >7 consecutive days during the 3 months prior to screening
Description

Pharmaceutical Preparations Affecting Glucose metabolism

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0596620
ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
Description

Weight-Loss Agents prescribed | Weight-Loss Agents Non-Prescription

Type de données

boolean

Alias
UMLS CUI [1,1]
C0376606
UMLS CUI [1,2]
C0278329
UMLS CUI [2,1]
C0376606
UMLS CUI [2,2]
C0013231
Retour au début de la page

Similar models

Eligibility Type II Diabetes NCT02429258

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes mellitus (t2dm)
boolean
C0011860 (UMLS CUI [1])
Metformin Dose Stable U/day | Insulin Dose Stable U/day | Antidiabetics Oral Quantity
Item
treated with either stable dose of metformin alone > or = to 1500mg/day or stable dose of insulin > or = to 30 units/day and up to 2oad medications for at least 8 weeks
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0456683 (UMLS CUI [1,4])
C0021641 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0456683 (UMLS CUI [2,4])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) 7.5% to 10.5% at screening
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) < or = to 45 kg/m2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Metformin Dose Stable | Antidiabetics Oral | Exception Metformin | Insulin regime
Item
for patients who enter the study taking a stable dose of metformin, history of taking oad medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C0557978 (UMLS CUI [4])
Insulin | Therapy Except Insulin | Therapy Except Antidiabetics Oral
Item
for patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 oad medications for 8 weeks prior to screening.
boolean
C0021641 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0332300 (UMLS CUI [2,2])
C0021641 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C0332300 (UMLS CUI [3,2])
C0935929 (UMLS CUI [3,3])
C1527415 (UMLS CUI [3,4])
Sulfonylureas
Item
use of sulfonylureas during the 8 weeks prior to screening
boolean
C0038766 (UMLS CUI [1])
Exposure to Dapagliflozin | Exposure to SGLT2 Inhibitor
Item
prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (sglt-2) inhibitor
boolean
C0332157 (UMLS CUI [1,1])
C2353951 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C3273807 (UMLS CUI [2,2])
Pharmaceutical Preparations Affecting Glucose metabolism
Item
ingestion of any medication know to affect glucose metabolism for >7 consecutive days during the 3 months prior to screening
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0596620 (UMLS CUI [1,3])
Weight-Loss Agents prescribed | Weight-Loss Agents Non-Prescription
Item
ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
boolean
C0376606 (UMLS CUI [1,1])
C0278329 (UMLS CUI [1,2])
C0376606 (UMLS CUI [2,1])
C0013231 (UMLS CUI [2,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial